12421226

Source:http://linkedlifedata.com/resource/pubmed/id/12421226

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003241, umls-concept:C0005768, umls-concept:C0005795, umls-concept:C0035668, umls-concept:C0039593, umls-concept:C0220847, umls-concept:C0430054, umls-concept:C1510438, umls-concept:C1705053
pubmed:issue	11
pubmed:dateCreated	2002-11-7
pubmed:abstractText	Two HCV antibody tests (EIA 2.0 [EIA2], Abbott; and the Version 3.0 ELISA [EIA3], Ortho) are currently licensed for screening of US blood donors. Testing of donors for HCV RNA allows comparison of the sensitivities of the two antibody-screening assays.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0417360
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Alanine Transaminase, http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers, http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis C Antibodies, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0041-1132
pubmed:author	pubmed-author:GalelSusan ASA, pubmed-author:GallardaJamesJ, pubmed-author:HollandPaul VPV, pubmed-author:KemperMartiM, pubmed-author:KuramotoIsamu KIK, pubmed-author:PietrelliLarryL, pubmed-author:StrongD MichaelDM, pubmed-author:TegtmeierGary EGE
pubmed:issnType	Print
pubmed:volume	42
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1507-13
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:12421226-Adult, pubmed-meshheading:12421226-Alanine Transaminase, pubmed-meshheading:12421226-Biological Markers, pubmed-meshheading:12421226-Blood Donors, pubmed-meshheading:12421226-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:12421226-Female, pubmed-meshheading:12421226-Follow-Up Studies, pubmed-meshheading:12421226-Genotype, pubmed-meshheading:12421226-Hepacivirus, pubmed-meshheading:12421226-Hepatitis C, pubmed-meshheading:12421226-Hepatitis C Antibodies, pubmed-meshheading:12421226-Humans, pubmed-meshheading:12421226-Immunoblotting, pubmed-meshheading:12421226-Immunoenzyme Techniques, pubmed-meshheading:12421226-Male, pubmed-meshheading:12421226-Mass Screening, pubmed-meshheading:12421226-Predictive Value of Tests, pubmed-meshheading:12421226-RNA, Viral, pubmed-meshheading:12421226-Reproducibility of Results, pubmed-meshheading:12421226-Sensitivity and Specificity, pubmed-meshheading:12421226-Seroepidemiologic Studies, pubmed-meshheading:12421226-Time Factors, pubmed-meshheading:12421226-United States, pubmed-meshheading:12421226-Viremia
pubmed:year	2002
pubmed:articleTitle	Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays.
pubmed:affiliation	Stanford Medical School Blood Center, Department of Pathology, Stanford University School of Medicine, Palo Alto, California 94304, USA. susangal@stanford.edu
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Multicenter Study